Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene and SpringWorks to Pair RAF and MEK Inhibitors in Solid Tumor Combo

publication date: Sep 6, 2018

BeiGene, a Beijing novel oncology company, will collaborate with New York's SpringWorks Therapeutics, combining BeiGene’s RAF inhibitor with SpringWorks' MEK inhibitor to treat patients with advanced solid tumors. BeiGene will be in charge of the initial Phase I global trial, though the two companies will split the costs evenly. SpringWorks will be responsible for a fixed-dose formulation of the combination therapy. More details....

Stock Symbols: (NSDQ: BGNE; HKEX: 6160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.